News|Articles|October 2, 2025

Q3 2025 Recap: Allergy News and Updates

Explore the latest advancements in allergy and immunology, including new therapies, FDA approvals, and innovative clinical strategies for improved patient care from Q3.

As Q3 closes, HCPLive revisits key advances in allergy and immunology, highlighting emerging therapies and practical clinical strategies. Over the past months, clinicians have gained insight into intranasal epinephrine for anaphylaxis, the expanding role of brief cognitive behavioral therapy (bCBT) for food allergy–related anxiety, and the integration of motivational interviewing to improve patient adherence and outcomes.

Related to this article

October 8th, 2026

Viaskin Peanut Patch FAQ: Where It Fits Beside Omalizumab and OIT

With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.

October 1st, 2026

4 Allergy Headlines You Missed in September 2026

From a CRISPR therapy's FDA priority review to oral HAE prophylaxis data and a needle-free epinephrine resubmission, 4 allergy stories from September.

October 7th, 2026

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

October 6th, 2026

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.

October 6th, 2026

Top Reason for Leaving HAE Attacks Untreated, Survey Finds

Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.

October 3rd, 2026

Q3 2026 Recap: Allergy News and Updates

Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.

October 8th, 2026

Tips on Optimizing HS Biologics, Combinations, and Surgery

Andrea Murina, MD, reviewed strategies for optimizing HS biologics, combining therapies, and reconsidering the role of surgery.

October 8th, 2026

Conference Preview: Fall Clinical Dermatology Conference 2026

HCPLive previews Fall Clinical 2026 in Las Vegas, October 8-11, with key sessions on atopic dermatitis, psoriasis, and vitiligo, plus expert interviews.